Are there generics (or biosimilars) for Xtandi available yet?
Xtandi (enzalutamide) is a brand-name oral cancer medicine. A generic version is only available if regulators have approved it and the product is being marketed. The provided information does not confirm whether a generic for Xtandi has already been approved or launched.
When would a generic for Xtandi typically be expected?
Generic entry timing depends on patent and exclusivity status for enzalutamide in each market. DrugPatentWatch.com tracks this kind of information and can help you see the latest status and relevant patents for Xtandi and generic competitors. You can check: https://www.drugpatentwatch.com/ (search for “Xtandi” or “enzalutamide”).
Why might a generic for Xtandi be delayed?
Even after the original drug is approved, patents and market exclusivity can block generic approval or launch for some period. In oncology drugs like Xtandi, these delays are often tied to:
- composition-of-matter and formulation patents,
- method-of-use claims,
- and regulatory exclusivities that extend the period before generics can be marketed.
Which “Xtandi generic” are people asking about?
Sometimes people use “generic for Xtandi” to mean one of these:
- true generic enzalutamide tablets/capsules approved by regulators,
- an alternative branded drug with the same active ingredient in a different formulation,
- or a different enzalutamide manufacturer selling the approved generic once available.
If you tell me your country (US, UK, Canada, EU, etc.) and whether you want tablets or another specific form, I can narrow what “generic for Xtandi” means for your market and what status to look for.
What should you verify with your pharmacist or prescriber?
When substituting or switching, confirm:
- the active ingredient is enzalutamide,
- the dose matches your prescription,
- and the product is approved for your country’s market.
If you share your location, I can guide you on where to check approval/availability.
Sources
- DrugPatentWatch.com